The NIAID Genomic Centers for Infectious Diseases (GCID) will provide insights into the biology of microbes, their role in pathogenesis, and their interactions with the host, including the microbiome by supporting a diverse set of genomic capabilities, such as next-generation sequencing and related genomic technologies.
The GCID will use and develop or improve innovative applications of genomic technologies, such as RNA sequencing and metagenomics, and provide rapid and cost-efficient production of high-quality genome sequences of microorganisms, invertebrate vectors of infectious diseases, and hosts and host microbiomes. Multiple strains and isolates of specific microbial species, populations and communities will be sequenced.
Genomes that will be sequenced include microorganisms from NIAID’s list of emerging and re-emerging infectious diseases, which includes NIAID Category A-C priority pathogens, clinical isolates, closely related species and strains, and invertebrate vectors of diseases.
Genomic capabilities include high-throughput next-generation sequencing, comparative genomic sequencing, single-nucleotide polymorphism identification, genotyping, and gene expression. The GCID will also provide methods and protocols developed for next-generation sequencing and related genomic technologies, in addition to bioinformatics software tools and analyses for studying infectious diseases with the intent to be used by the broad infectious diseases community.
Investigators interested in requesting sequencing, assembly, primary annotation, and analysis of microorganisms, invertebrate vectors of infectious diseases, and hosts and host microbiomes should submit a one page description of the project for consideration to Eun Mi Lee, firstname.lastname@example.org. Please include a justification and relevant background.
Information on accessing services from the Influenza Genome Sequencing Project can be found here.
Program-generated data and software will be made available through publicly accessible web and database sites, including the:
Reagents will be made available through BEI.
Last Updated February 10, 2015